Alexion Pharmaceuticals Inc.’s (ALXN) supplemental Biologics License Application for ULTOMIRIS for the treatment of people with atypical hemolytic uremic syndrome is under priority review, with a decision expected on October 19, 2019.Atypical hemolytic uremic syndrome (aHUS) is a genetic, chronic, ultra-rare disease that causes abnormal blood clots to form in small blood vessels in the kidneys. Historically, seventy-nine percent (79%) of all patients with aHUS died, required kidney dialysis, or had permanent kidney damage within three years after diagnosis.Soliris, also from the stable of Alexion is the first and only therapy approved for the treatment of atypical hemolytic uremic syndrome.ULTOMIRIS was approved as recently as December 2018 for the treatment of adults with a disease called Paroxysmal Nocturnal Hemoglobinuria, a rare acquired, life-threatening disease of the blood.The drug brought home sales of $78.8 million in the first half of 2019. Data and analytics company GlobalData expects sales of ULTOMIRIS to exceed $1 billion by 2021.ALXN closed Friday’s (Sep.27, 2019) trading at $97.77, down 0.94%.